Skip to Content

Canopy Growth Corp WEED

Morningstar Rating
CAD 8.84 −0.32 (3.49%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

US Deals Help Unlock Some Value but Doesn't Help Canopy Growth's Lagging Canadian Operations

Canopy Growth grows and sells cannabis products primarily in Canada, which accounts for roughly 50% of sales. Unfortunately, the Canadian market is overloaded with too many licensed producers, leading to tough price competition and a stubbornly robust illicit market, so Canopy has yet to reach profitability. We forecast mid-single-digit growth over the next decade for the Canadian market, driven by the conversion of illicit consumers into the legal market. We expect competition to ease as continued industry losses drive consolidation.

Price vs Fair Value

WEED is trading at a 450% premium.
Price
CAD 8.84
Fair Value
CAD 24.90
Uncertainty
Extreme
1-Star Price
CAD 99.00
5-Star Price
CAD 2.97
Economic Moat
Fhxv
Capital Allocation
Xhsy

Bulls Say, Bears Say

Bulls

Canopy Growth’s plans to create Canopy USA to strengthen its competitive position before US federal legalization.

Bears

While Canopy waits for US federal legalization to enter the THC market there, US multistate operators continue to grow bigger and become more competitive.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if WEED is a good fit for your portfolio.

News

Trading Information

Previous Close Price
CAD 9.16
Day Range
CAD 8.659.14
52-Week Range
CAD 3.7426.00
Bid/Ask
CAD 8.76 / CAD 8.85
Market Cap
CAD 673.59 Mil
Volume/Avg
847,760 / 3.1 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
2.22
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Doja, 7ACRES, Tweed, and Deep Space. Its non-THC products include skincare products under Martha Stewart CBD and Storz & Bickel vaporizers. Canopy growth merged its US assets into a separately operated holding company, Canopy USA, which will not be consolidated into the Canadian company's financials.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Core
Total Number of Employees
1,029

Competitors

Valuation

Metric
WEED
CRON
TLRY
Price/Earnings (Normalized)
1,432.96
Price/Book Value
1.610.830.38
Price/Sales
2.229.551.59
Price/Cash Flow
Price/Earnings
WEED
CRON
TLRY

Financial Strength

Metric
WEED
CRON
TLRY
Quick Ratio
1.0926.510.96
Current Ratio
1.5828.191.92
Interest Coverage
−3.63−4.39
Quick Ratio
WEED
CRON
TLRY

Profitability

Metric
WEED
CRON
TLRY
Return on Assets (Normalized)
−17.78%−0.28%−1.42%
Return on Equity (Normalized)
−46.87%−0.29%−1.82%
Return on Invested Capital (Normalized)
−16.41%−4.97%−0.92%
Return on Assets
WEED
CRON
TLRY
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Zoetis Inc Class A
ZTS
RksmswszvbPdvj$79.1 Bil
Merck KGaA ADR
MKKGY
YrvyctdhrhXwjmzr$72.0 Bil
Haleon PLC ADR
HLN
GcvthddjQvjr$37.3 Bil
Dr Reddy's Laboratories Ltd ADR
RDY
QgcdzrzjcWptl$12.8 Bil
Viatris Inc
VTRS
LpngrpxcxJmbl$12.7 Bil
Catalent Inc
CTLT
WszhbfvjbTgpdvqg$10.2 Bil
Perrigo Co PLC
PRGO
VjkqpmrzqRmcfd$3.5 Bil
Prestige Consumer Healthcare Inc
PBH
JdbwrqmstLgwky$3.4 Bil
Green Thumb Industries Inc
GTBIF
GrrwsmjklmFbywv$2.9 Bil
Curaleaf Holdings Inc
CURLF
DkyvhrvnSshhq$2.8 Bil

Sponsor Center